Physician profile
Anna Chung
NPI 1053535880
$1,847.55
in general payments reported to CMS, 2019-2025
25 companies · $802 in 2025
The $802 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2022: $374 · 2023: $222 · 2024: $219 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $373.32 | 2021-2025 | |
| Pfizer INC. | $240.67 | 2022-2025 | |
| Novo Nordisk INC | $214.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.06 | 2021-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $130.04 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $107.60 | 2021-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $92.95 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $70.39 | 2023-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $69.62 | 2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $48.44 | 2022-2023 | Shingrix |
| Abbott Laboratories | $47.44 | 2022 | |
| Grifols USA, LLC | $45.75 | 2021-2023 | Prolastin-C Liquid |
| Lilly USA, LLC | $45.71 | 2022-2025 | Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $28.11 | 2022-2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $19.10 | 2025 | Evkeeza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $18.21 | 2025 | Flucelvax, Fluad |
| Corcept Therapeutics | $17.72 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $15.63 | 2025 | Zoryve |
| Eisai INC. | $15.17 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.00 | 2021 | |
| Irhythm Technologies, INC. | $14.02 | 2021 | |
| Cranial Technologies, INC | $14.00 | 2022 | |
| Cequr Corporation | $12.56 | 2022 | |
| Echosens North America, INC. | $12.04 | 2025 | Fibroscan |
| Genentech USA, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.